pp65 and survivin are also being targeted together with EphA2 through a multi-peptide vaccine (ETAPA I) in HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated glioblastoma (NCT05283109, Table 3). The gene discussed is BIRC5; the disease is glioblastoma.